Navigation Links
Antipodean Pharmaceuticals Announces FDA Acceptance of IND for MitoQ(R)
Date:6/3/2008

SAN FRANCISCO, June 3 /PRNewswire/ -- Antipodean Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's Investigational New Drug (IND) application for its lead compound, MitoQ(R). With the IND acceptance, the Company will involve U.S. clinical centers in the development of MitoQ for the treatment of liver diseases such as non-alcoholic fatty liver disease (NAFLD).

"We look forward to working with FDA to further explore MitoQ's potential by conducting further trials in the United States," said Ken Taylor, Ph.D., Chief Executive Officer of Antipodean Pharmaceuticals. "The Company is actively seeking a pharmaceutical partner with whom to work to achieve this goal."

In April 2008, the Company announced positive results of a clinical study of MitoQ in patients with Hepatitis C virus (HCV) who had failed standard antiviral treatment. The data from this Phase 2 trial were presented at the European Association for the Study of Liver (EASL) conference. Results showed a significant reduction in elevated alanine aminotransferase (ALT) levels as compared to placebo. The ALT decrease from baseline was 26.4% (p<0.002) for patients in the 40mg dose group. This suggests that MitoQ can reduce necroinflammation and may halt disease progression to fibrosis or cirrhosis. The drug was well tolerated, with no significant safety issues.

About MitoQ(R)

MitoQ is a mitochondria-targeted antioxidant that selectively blocks mitochondrial oxidative damage and prevents liver cell apoptosis. MitoQ is based on a novel technology, targeted lipophilic cations that transport and concentrate antioxidants into the mitochondria-organelles inside cells that provide energy for life processes -- where they accumulate up to a thousand fold. MitoQ can reduce the hepatic oxidative damage that is induced by viral infection and that is also involved in the progression of Non-alcoholic Fatty Liver Disease (NA
'/>"/>

SOURCE Antipodean Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Antipodean Pharmaceuticals Announces Results of Phase 2 Study of Lead Compound MitoQ(R)
2. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
3. Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
4. Lotus Pharmaceuticals, Inc. Reaffirms its Confidence in Meeting its Make Good Target for Fiscal Year 2008
5. Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations
6. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
7. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results
8. Watson to Present at the UBS Global Specialty and Generic Pharmaceuticals Conference
9. Vanda Pharmaceuticals to Present at the FBR Capital Markets 12th Annual Spring Investor Conference
10. DURECT Corporation Presenting at the 2008 UBS Global Generic and Specialty Pharmaceuticals Conference
11. Vista Partners Initiates Coverage on Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/3/2008)...- Inc. Magazine recently included,Connolly Consult...ing,private companies in the country. The list is ...segment of the economy -- America,s,independent-mi...ies,represent the backbone of the U.S. economy., ...03/NY36880LOGO ), Connolly Consulting,s consiste...
(Date:10/3/2008)... Discrimination; Recognizes,Importance of Mental H.../PRNewswire-USNewswire/ -- Mental Health,America t...approval of a,mental health parity legislation tha...ion against Americans with mental health and subst...lans., The legislation, which recognizes the impo...
(Date:10/3/2008)...search Foundation(R) Collection of, Bouquets to T...Research, LOS ANGELES, Oct. 3 /PRNewswire/ -- Tel...g only hand-arranged, hand-delivered floral,arrang...nth-long,collaboration with The City of Hope, John... Cancer Center in southern California and national...
(Date:10/3/2008)...- As the population ages, a big,question employers...e the,financial crunch of an illness?", In most c...eck to,paycheck and now need two incomes to provid... spouses becomes critically ill and unable to work...ut the healthy,employee/spouse is strained by the ...
Breaking Medicine News(10 mins):Health News:Connolly Consulting Makes the 2008 Inc. Magazine's List of America's 5000 Fastest Growing Companies 2Health News:Mental Health America Hails Approval of Federal Parity Legislation 2Health News:Mental Health America Hails Approval of Federal Parity Legislation 3Health News:Teleflora and Nationally Recognized Hospitals to Honor Women Battling Breast Cancer 2Health News:Teleflora and Nationally Recognized Hospitals to Honor Women Battling Breast Cancer 3Health News:Can Your Employees Survive the Financial Crunch of an Illness? 2
...stressing events, bringing in its wake the possibi...d normal, reaction to the disease, but could have ...ion, depression has been considered to have an imp...initiation, of cancer. Reactive oxygen species (RO...
...nerative disorder with no known cause or cure, fir... time, we have come a long way in understanding th... by symptoms of memory loss, confusion, impaired j...ntation and loss of language skills. Mild cogniti...
...ely one in every 1,000 children and is characteriz...and environmental factors have been as causative f...tion typically occurs before the age of 16. There ...targeted treatment has been shown to improve sympt...
...monly known is a silent killer because it often go.... However, it can lead to a lot of complications s... if left untreated. Fortunately, it can be diagnos...reatment involves the use of anti-hypertensive med...
Other Medicine News:Health News:Depression May Be A Risk Factor For Cancer Initiation 2Health News:PET Scanning can help in early detection of Alzheimer’s diseas 2Health News:Guidelines for treatment of juvenile idiopathic arthritis formulated 2Health News:Common, cheaper drugs could be used to treat hypertension 2
(Date:10/6/2008)...oncept of Other Product - Company,s Bioabsorbable ... HONG KONG, Oct. 6 /- Data from mult...ing stent, OrbusNeich,s Genous Bio-engineered R,st...ter Cardiovascular,Therapeutics symposium, TCT 200...Ph.D., of the Academic Medical Center in,Amsterdam...
(Date:10/5/2008)... published in New England Journal of Medicine reaf...y profile of SPIRIVA(R),HandiHaler(R), RIDGEFIELD...lts of the,UPLIFT (Understanding Potential Long-te...wed that SPIRIVA(R) HandiHaler(R) (tiotropium brom...lung function for up to 4,years as measured by FEV...
(Date:10/3/2008)...AM, October 3 /- Amsterdam ...n the field of human gene therapy,announced today...to the,Marketing Authorization Application (MAA) f...PLD), a seriously debilitating and potentially let...hase II clinical studies (22,patients in total) de...
(Date:10/3/2008)...nies to Study B-Raf Kinase Inhibitors for Cancer T... Oct. 3 /-,Eli Lilly and Co...harmaceuticals, LLC today announced that the two c...ldwide licensing agreement related to,Deciphera,s ... study of,potential oncology therapeutics., The c...
Breaking Medicine Technology:Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 2Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 3Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 2Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 3Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 4Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 5Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 6AMT Intends to Incorporate Additional Data to its Marketing Authorization Dossier for Glybera(R) 2AMT Intends to Incorporate Additional Data to its Marketing Authorization Dossier for Glybera(R) 3Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement 2Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement 3Support for Patient Navigation Services to Help Cancer Patients 17607 1Support for Patient Navigation Services to Help Cancer Patients 17607 2Oberthur Technologies XPon Offer 3032 1Oberthur Technologies XPon Offer 3032 2Nanotubes grown straight in large numbers 4824 1Nanotubes grown straight in large numbers 4824 2Nanotubes grown straight in large numbers 4824 3President Recognizes Sharp HealthCare With 2007 Malcolm Baldrige National Quality Award at White House 17601 1President Recognizes Sharp HealthCare With 2007 Malcolm Baldrige National Quality Award at White House 17601 2
...atory and a worldwide leader in innovative laborat...sive test menu of highly complex and unique medica...by the University of Utah, ARUP Laboratories' clie...ity teaching hospitals and children's hospitals, m...
...atory and a worldwide leader in innovative laborat...sive test menu of highly complex and unique medica...by the University of Utah, ARUP Laboratories' clie...ity teaching hospitals and children's hospitals, m...
...atory and a worldwide leader in innovative laborat...sive test menu of highly complex and unique medica...by the University of Utah, ARUP Laboratories' clie...ity teaching hospitals and children's hospitals, m...
...atory and a worldwide leader in innovative laborat...sive test menu of highly complex and unique medica...by the University of Utah, ARUP Laboratories' clie...ity teaching hospitals and children's hospitals, m...
Medicine Products: